Background

One of the greatest challenges plants face during growth is the efficient allocation of limited metabolic energy. When energy is concentrated to promote growth, defense becomes weakened, and conversely, when the immune system is activated, growth halts. This trade-off between growth and defense is well recognized in the scientific community, and efforts to simultaneously secure productivity and resistance have continued. A representative substance regulating plant growth is the steroid hormone brassinosteroid (BR). Similar to how animal steroids suppress inflammation and immunity in the body, it is well known that BR in plants also suppresses immune responses during growth. However, the specific control pathway has remained a mystery. The precise mechanism by which immune receptor production is inhibited at the genetic level has not been clearly elucidated. Previous studies have only observed quantitative changes in hormones or the binding of proteins, without advancing to the stage of revealing fundamental changes in genome structure.

Key Findings

A recent paper published in the international journal PNAS revealed the mechanism by which a specific transcription factor controls epigenetic changes and RNA processing to regulate immunity when plants receive growth signals. The research team used the model plant Arabidopsis thaliana to observe molecular-level changes induced when the BR receptor, BRASSINOSTEROID INSENSITIVE 1 (BRI1), is activated. The results were intriguing. The basic helix-loop-helix (bHLH) transcription factor CESTA (CES) and its homologous proteins, BRASSINOSTEROID ENHANCED EXPRESSION (BEE1, BEE2, BEE3), were confirmed as the main regulators of immune suppression. These transcription factors block the activity of the core immune receptor gene SUPPRESSOR OF NPR1-1 CONSTITUTIVE 1 (SNC1). Specifically, they alter the DNA methylation pattern in the genome region rich in transposable elements (TE) near the SNC1 gene, effectively changing the gene's structure to prevent its expression. In this regulatory process, CES was found to physically interact with chromatin remodeling complexes and splicing machinery within the cell. This epigenetic interaction induces alternative splicing in the pre-mRNA processing stage of SNC1. As a result, inactive variant proteins are produced instead of normal immune receptor proteins, leading to a downregulation of the plant's overall defense system. To verify the operation of this regulatory circuit, the research team conducted gene knockout experiments. They created a triple mutant (ces-tM) lacking CES, BEE1, and BEE3, and a quadruple mutant (ces-qM) with BEE2 also knocked out, and directly compared their resistance to pathogens. The mutant plants showed significantly suppressed growth but exhibited remarkably strong resistance to the oomycete pathogen Hyaloperonospora arabidopsidis (Hpa) compared to the wild type. This phenomenon is interpreted as the immune suppression switch, previously tightly locked by growth-promoting hormone signals, being released, thereby normalizing the defense capability.

Implications and Prospects

This study provides a detailed control map of how plants decide whether to focus on growth or allocate resources to defense in response to environmental changes. Just as steroid hormones in animals function as key suppressors of immunity in the human body, it is now clear that plants also allocate energy intelligently through epigenetic control—an evolutionary strategy for resource allocation. However, there are still obstacles to overcome before this mechanism can be directly applied in agriculture. For instance, plants with genetically modified immunity maximization showed clear growth inhibition or dwarfism compared to the wild type. Therefore, the development of a precise switch that can release immune suppression only when pathogens invade, without impairing growth, is highlighted as a key future challenge. It is proposed that subsequent research should integrate gene editing technologies or chemical regulation methods to design systems where immune proteins function normally only under specific conditions.